Fig. 3

Depletion of CCR2 cells enhances tumor radiosensitivity. a Scheme of treatment. b Treated tumor was measured every 3-4 days for 33 days starting from the day of radiation (n = 10). c Percentage of mice still bearing tumor at the end of the treatments (n = 10), P < 0.05. d Flow cytometry profile of CCR2⁺Ly6C^hi in tumors 3 days post the start of treatments. Left, representative flow graph, gated on CD45⁺CD11b⁺cells; Middle, percentage of CD45⁺; Right, absolute number of cells (n = 4). NS, non-significant.*P < 0.05; **P < 0.01; ***P < 0.001. Each experiment was repeated 3 times. Data are presented as mean ± s.e.m